Macopharma
Macopharma, founded in 1977 in France, manufactures blood bag systems, pathogen inactivation technologies, sterile connection devices, separators, and processing software for blood banks and transfusion centers worldwide, generating €170 million in 2023 revenue across 84 countries.
- Company typePrivate
- Founded1977
- HeadquartersTourcoing, France
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Macopharma does
Macopharma, founded in 1977 in northern France and headquartered in Mouvaux (Tourcoing), is a privately held medical device company operating within the GMPi (Groupe Macopharma International) holding structure. The company designs, manufactures, and distributes an integrated portfolio of blood processing solutions covering single-use disposables (blood bag systems, filtration kits, pathogen inactivation sets, transfer/pooling/sampling sets), specialized equipment (MacoPress separators, MacoSeal tube sealers, Maconnect sterile connection devices, MacoTronic illumination devices), software for traceability and process data management, and validated processing guidelines sold to blood banks, blood transfusion centers, and hospitals.
The end customers are healthcare professionals in transfusion medicine, with named reference relationships including Canadian Blood Services, Vitalant, Belgian Red Cross, and EFS France, supported by a peer-reviewed publication cadence in Vox Sanguinis and Stem Cells Translational Medicine. Macopharma's portfolio is differentiated by a series of proprietary platforms: the DEHT/PAGGSM DEHP-free blood storage system positioned ahead of the EU REACH 2030 phase-out of DEHP-plasticized blood containers, the THERAFLEX MB-Plasma and THERAFLEX UV-Platelets pathogen inactivation systems, the SSP+ platelet additive solution used in more than 40 countries, and the Maconnect multi-sterile connection device. Production is anchored in France with additional manufacturing in Tunisia and Poland and a planned Serbia factory in 2025; the company reports 15 wholly-owned subsidiaries and distribution in more than 84 countries across five continents.
Revenue was reported at €170 million for 2023, generated primarily through B2B enterprise sales via direct field sales teams and regional subsidiaries using quote-based, multi-year contract pricing. The November 2024 acquisition of German blood-industry equipment maker Lmb Technologie (€8 million 2023 revenue) is intended to roughly double equipment business sales and consolidate the value chain between disposables, equipment, and software.
Macopharma firmographics
Firmographics- Name
- Macopharma
- Legal name
- Maco Pharma
- Website
- https://macopharma.com
- Company type
- Private
- Founded year
- 1977
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Macopharma, founded in 1977 in France, manufactures blood bag systems, pathogen inactivation technologies, sterile connection devices, separators, and processing software for blood banks and transfusion centers worldwide, generating €170 million in 2023 revenue across 84 countries.
- Ownership category
- akta.pro rank
Macopharma industry classification
Industry- Product category
- Blood Processing Medical Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Blood and Organ Banks (621991)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH)
- akta.pro secondary industries
- Diagnostic & Laboratory Packaging (Specimen Containers, Transport Tubes) (IMALAIAF), Sample Logistics, Biorepository & IVD Kit Management (Trial Support) (HLAGAEAI)
Keywords
Where Macopharma is headquartered
LocationHeadquarters
- HQ city
- Tourcoing
- HQ country
- France
- HQ region
- Europe
Offices17 records
Markets served
Macopharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Blood processing medical devices and disposables: Macopharma generates revenue primarily from the sale of single-use blood processing disposables including blood bag systems, filtration kits, pathogen inactivation sets, and transfer/pooling/sampling sets. 2023 sales of €170 million reported for Macopharma.
- Blood processing equipment: Sale of specialized equipment including MacoPress separators, MacoSeal sealers, Maconnect sterile connection devices, MacoTronic illumination machines. Lmb Technologie acquisition (2024) strengthens the equipment portfolio, targeting to double equipment business sales.
- Software and data management: Software products including data management systems for traceability (Macopress Smarter), as part of integrated blood processing solutions. Lmb Technologie contributes software portfolio (agitators, separators, welders, accessories).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B enterprise pricing via direct sales and subsidiary channels |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Macopharma product offering
Product offeringCore offering
Macopharma manufactures and sells blood processing medical devices and single-use disposables (blood bag systems, filtration kits, pathogen inactivation sets, transfer/pooling/sampling sets) along with specialized equipment (blood component separators, tube sealers, sterile connection devices, UV illumination machines) and software for traceability. The company serves blood banks, hospitals, and blood transfusion centers across 84 countries with solutions covering collection, separation, leukodepletion, pathogen inactivation, cord blood processing, and platelet preparation.
Differentiator
Problem solved
Functional benefit
Brands
- INNOV by Macopharma: Innovation committee and process that empowers collaborators, partners and stakeholders to contribute from ideation to incubation and approval phases
- MacoSeal
- Maconnect
- MacoPress
- DEHT x PAGGSM
- THERAFLEX
- MacoTronic
Companies that use Macopharma
Customer profileNamed customers4 records
Segments1 record
Ideal customer profiles1 record
Macopharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
Macopharma partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor and core.
- LMB SoftminorLocal Serbian firm LMB Soft is partnering with Macopharma to build a new factory in Niš, Serbia. The expansion includes extending facilities and creating around 30 new high-value jobs primarily for technical university graduates by end of 2025.
- Lmb TechnologiecoreThe international GMPi/Macopharma group acquired German company Lmb Technologie in November 2024. Lmb Technologie (founded 1979, €8m sales in 2023) is a major player in blood industry equipment including agitators, separators, welders and software. The acquisition strengthens Macopharma's equipment range, enabling coverage of the entire blood processing value chain. Synergies expected to double equipment business sales. Lmb brings exclusivity of equipment in defined geographical areas of Macopharma's 5-year strategy. Expected to complete in early 2025.
- Canadian Blood ServicescoreMultiple collaborative research studies conducted with Canadian Blood Services (Product & Process Development, Ottawa/Vancouver/Edmonton) and their NetCAD Blood4Research facility. Studies include DEHT/PAGGSM vs DEHP/SAGM RBC quality comparison, bacterial proliferation studies, and hemolysis measurement methodology. Macopharma employees co-authored published studies in Vox Sanguinis.
- Vitalant Innovation CentercoreFirst US evaluation of Buffy Coat-derived platelets using whole blood processing with 24-hour hold was conducted at Vitalant Innovation Center in Denver, CO in collaboration with Macopharma. This study was critical for demonstrating the feasibility of adopting European buffy coat methods in US blood centers to maximize whole blood utilization and address platelet shortages.
- Belgian Red Cross – Service du SangcoreCollaborative multicenter study on DEHT/PAGGSM impact on RBC concentrate quality conducted with Belgian Red Cross (Service du Sang, Namur, Belgium). Joint research examining whole blood processing, storage studies up to 49 days, and quality parameter testing. Co-authors from Belgian Red Cross on peer-reviewed publication.
- EFS Bourgogne Franche ComtécoreCollaborative research partner on DEHT/PAGGSM RBC quality studies, comparative SAGM vs PAGGSM studies, and process preparation impact assessments. EFS Besançon conducted whole blood processing via pool and split methods, contributing to multicenter studies with Macopharma R&D and Belgian Red Cross.
- INSERMminorINSERM (Institut national de la santé et de la recherche médicale, France) collaborated on the comparative study of SAGM vs PAGGSM storage solutions, focusing on storage-induced micro-erythrocytes and haematocrit measurement discrepancies. Contributed scientific expertise on RBC morphology research.
- Canadian Blood Services' NetCAD Blood4ResearchcoreNetCAD Blood4Research program of Canadian Blood Services collaborated on sampling pouch hemolysis measurement comparative study. Initial observation at NetCAD about expected hemolysis measurement increase when using Macopharma's sampling pouch method led to the comparative study. Study published in Vox Sanguinis.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Macopharma competitors and assessment
Company assessmentDirect peers
- Bio-Rad Laboratories: Bio-Rad's clinical diagnostics division supplies blood-typing reagents and quality-control products to blood banks, directly overlapping Macopharma's transfusion-medicine customer base.
- Haemonetics Corporation: Haemonetics supplies blood and plasma component collection devices, software, and hospital-based blood-management systems. Competes directly with Macopharma's MacoPress/MacoTronic equipment, software, and consumables.
- Immucor: Immucor specializes in transfusion and transplantation diagnostics, including reagents used in blood-bank workflows. Adjacent competitor to Macopharma for blood-center customers, with overlap in immunohematology.
- Fresenius Kabi: Fresenius Kabi's Transfusion Medicine and Cell Technologies unit manufactures blood-collection bags, filters, separators, and storage solutions — direct overlap with Macopharma's disposable and equipment portfolio.
- Grifols: Grifols operates a blood-bags and disposables business alongside its plasma products franchise, competing with Macopharma in DEHP/DEHP-free blood bag systems for blood banks and transfusion centers.
- Asahi Kasei Medical: Asahi Kasei Medical produces Planova and related virus filters used in plasma and biotech processing. Competes with Macopharma's Leucoflex and blood-filtration product lines in adjacent filtration markets.
- Cerus Corporation: Cerus is the developer of the INTERCEPT pathogen-reduction system for platelets and plasma — a direct competing platform to Macopharma's THERAFLEX MB-Plasma and UV-Platelets systems.
- Terumo BCT (Terumo Corporation): Terumo BCT is the leading global supplier of blood component collection, processing, and storage systems (incl. apheresis, whole-blood processing, and pathogen reduction). Head-to-head competitor to Macopharma across blood bags, separators, and PI equipment.
Broad incumbents
- Octapharma: Octapharma is a major plasma-products manufacturer with growing activity in cell and gene therapies. Broader incumbent than Macopharma in the blood-products value chain with some overlap on the supply side of plasma used in transfusion.
- Hologic: Hologic's Diagnostic Solutions division operates blood-bank molecular screening assays (e.g., Procleix). Competes with Macopharma for blood-bank spend across adjacent diagnostic categories rather than disposables/equipment.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Macopharma social profiles
Digital presenceMacopharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Macopharma leadership team
Management profileNumber of profiles
Profiles15 records
Macopharma subsidiaries and ownership
Company hierarchySubsidiaries15 records
Macopharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Macopharma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Macopharma
What does Macopharma do?
Macopharma manufactures and sells blood processing medical devices and single-use disposables (blood bag systems, filtration kits, pathogen inactivation sets, transfer/pooling/sampling sets) along with specialized equipment (blood component separators, tube sealers, sterile connection devices, UV illumination machines) and software for traceability. The company serves blood banks, hospitals, and blood transfusion centers across 84 countries with solutions covering collection, separation, leukodepletion, pathogen inactivation, cord blood processing, and platelet preparation.
Is Macopharma a public or private company?
Macopharma is a private company. It is classified as corporate owned and is currently operating.
When was Macopharma founded?
Macopharma was founded in 1977. It employs 1,001 to 5,000 people.
Where is Macopharma based?
Macopharma is headquartered in Tourcoing, France, in the Europe region.
How does Macopharma make money?
Three revenue lines are on record. Blood processing medical devices and disposables are the primary driver. The others are blood processing equipment and software and data management.
Who are Macopharma's main competitors?
Direct peers on record are Bio-Rad Laboratories, Haemonetics Corporation, Immucor, Fresenius Kabi, Grifols, Asahi Kasei Medical, Cerus Corporation and Terumo BCT (Terumo Corporation). Broad incumbents are Octapharma and Hologic.
Does Macopharma have an API?
No public API is recorded for Macopharma.
What industry is Macopharma in?
Macopharma's product category is Blood Processing Medical Devices. Its primary akta.pro industry code is HLAHAAAH, Blood Bank, Transfusion Medicine & Immunohematology, with a secondary code of IMALAIAF, Diagnostic & Laboratory Packaging (Specimen Containers, Transport Tubes). Its NAICS code is 3391 and its SIC code is 3841.